dihexa human trials or clinical studies status 2026 dihexa human trials dihexa human clinical trials 2026 Umbrella Lab Announces Documentation And Traceability Update For Dihexa Peptide-ch Unlocking the Potential of Dihexa

WADA's S0 category prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." Because Selank is not approved by the FDA, EMA, or other major Western regulatory authorities, it could be classified as a prohibited non-approved substance under S0, even though it is approved in Russia

Isakova AM, Kutyrev MA, Kudasheva AS, Rogacheva EV, Kraeva LA, Shityakov S, Zhukov MV, Ulasevich SA, Skorb EV (2025) Fabrication of biocidal materials based on the molecular interactions of tetracycline and quercetin with hydroxyapatite via in silico-and in vitro approaches

TB-500 (thymosin beta-4) TB-500 is a synthetic fragment of thymosin beta-4

But 13 hours is still short enough to require daily dosing

Source data have been provided for Fig